Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
0.9908
-0.0082 (-0.82%)
Jan 22, 2026, 2:27 PM EST - Market open
Biofrontera Revenue
Biofrontera had revenue of $6.99M in the quarter ending September 30, 2025, a decrease of -22.46%. This brings the company's revenue in the last twelve months to $37.17M, up 5.11% year-over-year. In the year 2024, Biofrontera had annual revenue of $37.32M with 9.54% growth.
Revenue (ttm)
$37.17M
Revenue Growth
+5.11%
P/S Ratio
0.25
Revenue / Employee
$399,613
Employees
93
Market Cap
11.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 37.32M | 3.25M | 9.54% |
| Dec 31, 2023 | 34.07M | 5.40M | 18.82% |
| Dec 31, 2022 | 28.67M | 4.57M | 18.98% |
| Dec 31, 2021 | 24.10M | 5.25M | 27.86% |
| Dec 31, 2020 | 18.85M | -7.33M | -28.01% |
| Dec 31, 2019 | 26.18M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Flora Growth | 57.61M |
| IM Cannabis | 37.61M |
| Sunshine Biopharma | 37.32M |
| cbdMD | 19.19M |
| Sonoma Pharmaceuticals | 16.94M |
| RedHill Biopharma | 9.55M |
| China Pharma Holdings | 4.05M |
| China SXT Pharmaceuticals | 1.54M |
BFRI News
- 9 days ago - Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth - GlobeNewsWire
- 14 days ago - Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones - GlobeNewsWire
- 5 weeks ago - Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio - GlobeNewsWire
- 7 weeks ago - Last Patient Completes Biofrontera's Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities - GlobeNewsWire
- 7 weeks ago - Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT - GlobeNewsWire
- 2 months ago - Biofrontera Inc. (BFRI) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 2 months ago - Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M - GlobeNewsWire